BioCardia, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BCDA research report →
Companywww.biocardia.com
BioCardia, Inc. , a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease.
- CEO
- Peter A. Altman
- IPO
- 1996
- Employees
- 17
- HQ
- Sunnyvale, CA, US
Price Chart
Valuation
- Market Cap
- $5.33M
- P/E
- -1.28
- P/S
- 0.00
- P/B
- -9.33
- EV/EBITDA
- -0.65
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -5456.14%
- ROIC
- 1195.41%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-8,228,000 · -3.55%
- EPS
- $-1.23 · 57.59%
- Op Income
- $-8,278,000
- FCF YoY
- 7.33%
Performance & Tape
- 52W High
- $2.45
- 52W Low
- $0.84
- 50D MA
- $1.16
- 200D MA
- $1.38
- Beta
- 0.55
- Avg Volume
- 162.43K
Get TickerSpark's AI analysis on BCDA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 18, 26 | Altman Peter | buy | 5,700 |
| May 15, 26 | Altman Peter | buy | 5,100 |
| Apr 29, 26 | Altman Peter | buy | 5,000 |
| Apr 21, 26 | Altman Peter | buy | 400 |
| Apr 20, 26 | Altman Peter | buy | 600 |
| Mar 25, 26 | Altman Peter | buy | 300 |
| Mar 24, 26 | Altman Peter | buy | 600 |
| Feb 4, 26 | Altman Peter | buy | 5,000 |
| Jan 21, 26 | Altman Peter | buy | 300 |
| Jan 20, 26 | Altman Peter | buy | 600 |
Our BCDA Coverage
We haven't published any research on BCDA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BCDA Report →